Abstract��OBJECTIVE To explore the working mode of clinical pharmacists participating in multidisciplinary team (MDT) for cancer patients.METHODS A breast cancer physician leaded the team, comprised of an imageology specialist, an endocrinology specialist and a clinical pharmacist carried on the multidisciplinary discussions of a breast cancer patient at reproductive age with morbid obesity, focusing on the four aspects of morbid obesity, infertility, chemotherapeutic doses and application of dexamethasone. Clinical pharmacist evaluated the risk of medication in the patient and participated in the entire process of anti-tumor therapy.RESULTS After multidisciplinary discussions, we determined the patient treatments and drug applications, the patient successfully completed the first cycle of anti-tumor therapy with no serious adverse reactions.CONCLUSION As one of the important members of multidisciplinary team, the clinical pharmacist could cooperate with other physicians by taking the advantages of pharmacy, and initially could form the working mode of multidisciplinary diagnosis and treatments of cancer patients.
����,��÷. ���������ٰ�Ů�Ի��߰鲡̬���ֵĶ�ѧ������ģʽ[J]. �й�ҩѧ��־, 2018, 53(13): 1130-1136.
JIN Yao, DONG Mei. MDT Model of a Breast Cancer Patient at Reproductive Age with Morbid Obesity. Chinese Pharmaceutical Journal, 2018, 53(13): 1130-1136.
PERGOLA G D, SILVESTRIS F. Obesity as a major risk factor for cancer[J]. J Obesity, 2013, 2013(13):291546.
[2]
WANG W J. Report of cancer incidence and mortality in China, 2016[J/OL]. J Clin Med Liter(Elec Ed)(�ٴ�ҽҩ��������־), 2017, 4(19):3604.
[3]
ANDERS C K, JOHNSON R, LITTON J, et al. Breast cancer before age 40 years[J]. Semin Oncol, 2009, 36(3):237-249.
[4]
MCCRAY D K, SIMPSON A B, FLYCKT R, et al. Fertility in women of reproductive age after breast cancer treatment: practice patterns and outcomes[J]. Annals Surg Oncol, 2016, 23(10):1-7.
[5]
BINES J, OLESKE D M, COBLEIGH M A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer[J]. J Clin Oncol Off J Am Society Clin Oncol, 1996, 14(5):1718-1729.
[6]
AKDUMAN A T, OZERKAN K, ZIK B, et al. Effect of tamoxifen on ovarian reserve: a randomized controlled assessor-blind trial in a mouse model[J]. J Turkish German Gynecol Assoc, 2014, 15(4):228-232.
[7]
National Comprehensive Cancer Network[Z]. 2016. www. nccnorg. Accessed Feb 16, 2016.
[8]
SHAH S, DOWELL J, GREENE S. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting[J]. Ann Pharm, 2006, 40(9):1527-1533.
[9]
KHANAL S, POUDEL A K, PALAIAN S. Oncology pharmacy practice in a teaching hospital in nepal[J]. J Oncol Pharm Pract, 2010, 16(2):75-79.
[10]
BINES J, OLESKE D M, COBLEIGH M A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer[J]. Matuvitas, 1996,25(2):156-157.
[11]
BEN-AHARON I, BAR-JOSEPH H, TZARFATY G, et al. Doxorubicin-induced ovarian toxicity[J]. Rep Biol Endocrinol, 2010, 8(1):1-7.
[12]
MEIROW D, LEWIS H, NUGENT D, et al. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool[J]. Human Reprod, 1999, 14(7):1903-1907.
[13]
REH A, OKTEM O, OKTAY K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers[J]. Fertility & Sterility, 2008, 90(5):1635-1639.
[14]
BARJOSEPH H, BENAHARON I, RIZEL S, et al. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes[J]. Reprod Tox, 2010, 30(4):566-572.
[15]
TING A Y, PETROFF B K. Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat[J]. J Assisted Reprod Genetics, 2010, 27(11):591-597.
[16]
BAR-JOSEPH H, BEN-AHARON I, TZABARI M, et al. In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels[J]. PLoS One, 2011, 6(9):e23492.
[17]
TARUMI W, SUZUKI N, TAKAHASHI N, et al. Ovarian toxicity of paclitaxel and effect on fertility in the rat[J]. J Obstet Gynaecol Res, 2009, 35(3):414-420.
[18]
FU X W, SHI W Q, ZHANG Q J, et al. Positive effects of taxol pretreatment on morphology, distribution and ultrastructure of mitochondria and lipid droplets in vitrification of in vitro matured porcine oocytes[J]. Animal Reprod Sci, 2009, 115(1):158-168.
[19]
SILVA C, CARAMELO O, ALMEIDA-SANTOS T, et al. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and Meta-analysis[J]. Human Reprod, 2016, 31(12):2737-2749.
[20]
SAWYER M, RATAIN M J. Body surface area as a determinant of pharmacokinetics and drug dosing[J]. Investigational New Drugs, 2001, 19(2):171-177.
[21]
DOOLEY M J, POOLE S G. Poor correlation between body surface area and glomerular filtration rate[J]. Cancer Chemother Pharm, 2000, 46(6):523-526.
[22]
GRIGGS J, MANGU P, TEMIN S, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline[J]. J Oncol Pract, 2012, 8(4):59-61.
[23]
ROILA F, MOLASSIOTIS A, HERRSTEDT J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients[J]. Annal Oncol, 2016, 27(Suppl 5):v119-v133.
[24]
YU S Y, YIN J L, QIN S K, et al. Guidelines for the prevention and treatment of vomiting related to cancer treatment (2014 Edition)[J]. Chin Clin Oncol(�ٴ�����ѧ��־), 2014(3):263-273.
[25]
CELIO L, BONIZZONI E, BAJETTA E, et al. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: Meta-analysis of individual patient data examining the effect of age on outcome in two phase �� trials[J]. Support Care Cancer, 2013,21(2):565-573.
[26]
ZHANG L, TAN L, LU J. The expert consensus of off-labeled drug uses[J]. Adv Drug React J(ҩ�ﲻ����Ӧ��־), 2015,17(2):101-103.
[27]
NI G H, ZHANG J, ZHENG F T. Status and trends of Chinese obesity epidemic[J]. Food Nutrit China(�й�ʳ����Ӫ��), 2013,19(10):70-74.
[28]
GATHIRUA-MWANGI W G, SONG Y, MONAHAN P, et al. Associations of Metabolic syndrome and C�\reactive protein with Mortality from total cancer, obesity-linked cancers and Breast Cancer among Women in NHANES ��[J/OL]. International J Cancer, [2018-2-27]. https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31344.
[29]
DU B D, DU B E. A formula to estimate the approximate surface area if height and weight be known[J]. Nutrition, 1916, 5(5):303-311.
[30]
PORTER D J, WILSON M. Effect of capping chemotherapy dose on chemotherapy effect in morbidly obese women with breast cancer[J]. J Clin Oncol, 2013,31(15):1081.
[31]
MADAMAS Y, SAWKA C A, FRANSSEN E, et al. Are medical oncologists biased in their treatment of the large woman with breast cancer[J]. Breast Cancer Res Treat, 2001, 66(2):123-133.
[32]
ABDAH-BORTNYAK R, TSALIC M, HAIM N. Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability[J]. Med Oncol, 2003, 20(4):363-368.
[33]
LOPES-SERRAO M D, USSERY S M, SHAH S R. Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing[J]. J Oncol Practice, 2011, 7(1):13-17.
[34]
ROSNER G L, HARGIS J B, HOLLIS D R, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541[J]. J Clin Oncol, 1996, 14(11):3000-3008.
[35]
COLLEONI M, LI S, GELBER R D, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index[J]. Lancet, 2005, 366(9491):1108-1110.
[36]
GEORGIADIS M S, STEINBERG S M, HANKINS L A, et al. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer[J]. Jnci J Nat Cancer Inst, 1995, 87(5):361-366.
[37]
POIKONEN P, BLOMAVIST C, JOENSUU H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area[J]. Acta Oncol, 2001, 40(1):67-71.
[38]
GRIGGS J J, SORBERO M E, LYMAN G H. Undertreatment of obese women receiving breast cancer chemotherapy[J]. Arch Inter Med, 2005, 165(11):1267-1273.
[39]
HOURDEQUIN K C, SCHPERO W L, MCKENNA D R, et al. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and Meta-analysis[J]. Anna Oncol, 2013, 24(12):2952-2962.
[40]
WANG K, GUO X. Present situation and prospect of the clinical pharmaceutical work in our hospital[J]. China Mod Med(�й�����ҽҩ), 2012,19(2):163-164.
[41]
HU X L, ZHAN S P, WANG Y, et al. Polypharmacy management and pharmaceutical care of clinical pharmacists participating in the team of comprehensive geriatric assessment[J]. Chin Pharm J(�й�ҩѧ��־), 2017, 52(4):323-326.
[42]
JIAN L Y, HE X J. Exploration of hospital pharmacy tendency in future[J]. Chin J Hosp Pharm(�й�ҽԺҩѧ��־), 2015, 35(20):1803-1806.
[43]
LIU J Y, HE Y Y, JIANG A H, et al. Practice and analysis of clinical pharmacists participating in consultation[J]. Chin J Clin Rat Drug Use(�ٴ�������ҩ��־), 2017, 10(6):99-100.
[44]
GUAN Z S, ZHOU X T. Perspectives on clinical pharmacists�� participating in consultation on the use of antibiotics in 227 cases[J]. J China Pharm(�й�ҩ��), 2009,20(17):1358-1360.
[45]
LIAO Y, WEI N, PAN H M. Case analysis of clinical consultation of special grade[J]. Chin J Hosp Pharm(�й�ҽԺҩѧ��־), 2014, 34(4):315-318.
[46]
XIE H, MA Z L, CHEN Z X, et al. Role and work mode of clinical pharmacists in the multidisciplinary pain management team[J]. Pharm Clin Res(ҩѧ���ٴ��о�), 2015(3):331-336.
[47]
OCVIRK J, BOC M, REBERSEK M, et al. Cisplatin-induced non-convulsive posterior reversible encephalopathy syndrome in a 41-year-old woman with metastatic malignant melanoma[J]. Radiol Oncol, 2009, 43(2):120-125.
[48]
GOLDSPIEL B R, DECHRISTOFORO R, DANIELS C E. A continuous-improvement approach for reducing the number of chemotherapy-related medication errors[J]. Am J Healt-system Phar, 2000,57(Suppl 4):S4-S9.
[49]
LIU M, YAN J Q, ZHANG Y, et al. Role and thinking of pharmacists in pharmaceutical affairs management at cancer hospital and quality control based on new health care reform background[J]. Chin Pharm J(�й�ҩѧ��־), 2018, 53(2):154-158.
2018, Vol. 53 
